Topical Minocycline for CARP

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date pushed from Oct 15, 2026 to Dec 15, 2026
  2. Start date: Sep 15, 2026 to Oct 15, 2026
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Publications: details revised at 2 of 5 entries
  3. Start date: Jun 1, 2026 to Sep 15, 2026
    • Primary completion pushed from Jun 2027 to Aug 2027
    • Study completion pushed from Dec 2027 to Feb 2028
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This proof-of-concept trial evaluates the efficacy, safety, and patient satisfaction of topical minocycline foam (AMZEEQ®) in patients aged 9 and older with confluent and reticulated papillomatosis (CARP). Participants will apply AMZEEQ® to one side of the body and a topical emollient to the other for 5 weeks, followed by an optional extension period. The study aims to assess whether topical minocycline is a well-tolerated and effective alternative to oral antibiotics.
Trial Details
NCT Number NCT07462702
Lead Sponsor Medical University of South Carolina
Collaborators: Journey Medical Corporation
Conditions
(from sponsor)		 Confluent and Reticulated Papillomatosis (CARP)
Related terms cyclopia sequence, Papillomatosis, Familial Cutaneous, Pruritus
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov